The Drug Cell (TDC) marks a major breakthrough in the field of cell therapies in Europe. This new French alliance brings together key players in biotechnology and innovation to develop scalable and accessible therapeutic solutions. As part of the France 2030 initiative, TDC aims to advance research, development, and industrial deployment, with the first clinical trials planned by 2030 and market entry expected in 2034.
This pioneering ecosystem integrates cutting-edge technologies such as automation, artificial intelligence, and digital manufacturing, ensuring real-time quality control and enhanced scalability. Among the major innovations, Digital Twin technology will be implemented from the early stages, enabling real-time monitoring and optimization of treatments before patient testing.
The Drug Cell unites nine leading French biotech and innovation players, including Etablissement Français du Sang (EFS), Centre d’Étude des Cellules Souches/I-Stem, Gpi France, Carroucell, EVerZom, MGA Technologies, University of Montpellier, CHU of Montpellier, and CHU of Rennes. These organizations will collaborate to establish France and Europe as leaders in regenerative medicine.
For more details, read the full press release.
In the Same Field
Stäubli Technical Days 2025
We will be attending the Stäubli Technical Days 2025! Rochexpo – La Roche-sur-Foron (74) 8–11 December 2025 We invite you to come and discover the 7th edition of the Stäubli Technical Days, a highlight event focusing on robotics, automation and industrial innovation....
Industry Week 2025
At MGA, we are building the future together! For two weeks, our company had the pleasure of opening its doors to the younger generation and those involved in education. Middle school pupils, high school pupils, teachers: many of you came to discover our professions,...